March 2013 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” This study found that screening for prostate cancer did not significantly reduce prostate cancer-specific mortality in a meta-analysis of five randomized controlled trials, although one trial reported a benefit in a specific age subgroup.
1 citations
,
October 2009 in “Cancer Epidemiology Biomarkers & Prevention” This review discusses the American Society of Preventive Oncology's focus on cancer prevention and highlights the ongoing challenges and developments in screening, tobacco control, and the need for innovative risk-reduction strategies; it reports no new research findings.
April 2012 in “The Journal of Urology” This study modeled how differences in trial settings and protocols, such as biopsy compliance and control arm screening, can explain the varying prostate cancer mortality reductions observed in the ERSPC and PLCO trials.
December 2010 in “Cancer Prevention Research” This study provides evidence supporting the feasibility of presurgical, window-of-opportunity models to evaluate the preventive potential of candidate agents in cancer, using cases from breast, prostate, and colorectal settings.
54 citations
,
January 2021 in “Biophysics Reports” This review highlights the current progress and application pros and cons of various cell-based screening platforms in drug discovery, discussing challenges and potential improvements for these innovative methods.
